7,8‐Dihydroxyflavone Suppresses Experimental Pulmonary Fibrosis by Inhibiting Fibroblast‐to‐Myofibroblast Transformation and Epithelial–Mesenchymal Transition
Basic & Clinical Pharmacology & Toxicology · 2026
DOI: 10.1111/bcpt.70158 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2026. Verfasst von Yu-Chen Song und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Northern Jiangsu People's Hospital, Yangzhou, China. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Flavones, Pulmonary Fibrosis, Fibroblasts. Die Arbeit nennt 35 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Bethune Charitable Foundation.
Abstract (Originalsprache)
Pulmonary fibrosis (PF) is a chronic and progressive fibrotic disease with limited treatment options, which highlights the urgent need for novel therapeutic strategies. Fibroblast‐to‐myofibroblast transformation (FMT) and epithelial–mesenchymal transition (EMT) are central mechanisms driving fibrosis progression. This study investigated the therapeutic potential and mechanisms of 7,8‐dihydroxyflavone (7,8‐DHF), a selective tropomyosin receptor kinase B (TrkB) agonist, in experimental PF models in vitro and in vivo. Human lung fibroblast cells (MRC‐5) and mouse lung epithelial cells (MLE‐12) were stimulated with transforming growth factor‐β1 (TGF‐β1). 7,8‐DHF suppressed the migration, proliferation and differentiation of TGF‐β1‐induced MRC‐5 cells as well as reduced the protein levels of fibrotic markers including α‐smooth muscle actin, connective tissue growth factor, collagen I and fibronectin. Moreover, 7,8‐DHF attenuated the migration and EMT of TGF‐β1‐induced MLE‐12 cells. Additionally, 7,8‐DHF alleviated bleomycin‐induced PF in mice. Mechanistically, 7,8‐DHF inhibited the TGF‐β1/Smad2/3 signalling pathway in both models. Notably, the anti‐fibrotic effects were not reversed by the selective TrkB inhibitor ANA‐12, suggesting TrkB‐independent action. Instead, 7,8‐DHF suppressed Akt activity in MRC‐5 and MLE‐12 cells. These findings demonstrate that 7,8‐DHF alleviates PF by targeting FMT and EMT via TGF‐β1/Smad2/3 signalling and Akt inhibition. These results highlight 7,8‐DHF as a promising therapeutic candidate for PF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Northern Jiangsu People's Hospital, Yangzhou, China.
- Yangzhou Key Laboratory of Clinical Pharmacy and Drug Research, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, China.
- Medical College, Yangzhou University, Yangzhou, China.
- School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
- College of Pharmacy, Dalian Medical University, Dalian, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- Bethune Charitable Foundation
Zitieren
APA
Song, Y. C., Li, Q. L., Liang, R. J., Yao, J. T., Tian, Z., Hu, Y. W., Tan, T. T., Jia, D. X., Guo, D. D., Zhu, H., Zhao, J., & Hang, P. Z. (2026). 7,8‐Dihydroxyflavone Suppresses Experimental Pulmonary Fibrosis by Inhibiting Fibroblast‐to‐Myofibroblast Transformation and Epithelial–Mesenchymal Transition. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70158
Vancouver
Song YC, Li QL, Liang RJ, Yao JT, Tian Z, Hu YW, et al. 7,8‐Dihydroxyflavone Suppresses Experimental Pulmonary Fibrosis by Inhibiting Fibroblast‐to‐Myofibroblast Transformation and Epithelial–Mesenchymal Transition. Basic & Clinical Pharmacology & Toxicology. 2026. doi:10.1111/bcpt.70158
BibTeX
@article{Song2026,
author = {Song, Yu-Chen and Li, Qing-Liu and Liang, Ru-Jin and Yao, Jia-Tong and Tian, Zhen and Hu, Yu-Wei and Tan, Ting-Ting and Jia, Dong-Xu and Guo, Dan-Dan and Zhu, Hua and Zhao, Jing and Hang, Peng-Zhou},
title = {7,8‐Dihydroxyflavone Suppresses Experimental Pulmonary Fibrosis by Inhibiting Fibroblast‐to‐Myofibroblast Transformation and Epithelial–Mesenchymal Transition},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2026},
doi = {10.1111/bcpt.70158}
}
EUVIMED